Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

FDA approves adalimumab biosimilar Hyrimoz

Nov. 5, 2018

ASP-5094 safe and well tolerated in patients with rheumatoid arthritis on methotrexate

Oct. 29, 2018

Dual ICOS/CD28 antagonist demonstrates efficacy in models of autoimmune disease

Oct. 29, 2018

SpinalCyte presents 12-month data from phase I/II study of CybroCell in degenerative disc disease

Oct. 26, 2018

Phase IIb study of SM-04690 in knee osteoarthritis meets primary endpoints

Oct. 25, 2018

Results from the phase IIb RISE-SSc study of riociguat presented

Oct. 25, 2018

Disruption of actin-binding by PLS3 mutations causes congenital diaphragmatic hernia

Oct. 23, 2018

Topline results from phase IIb study of dapirolizumab pegol in SLE

Oct. 23, 2018

Prdx6 as a new therapeutic target to restore muscle loss in type 2 diabetes-associated sarcopenia

Oct. 23, 2018

Phase II study of rozanolixizumab achieves proof of concept in myasthenia gravis

Oct. 18, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...